Although sera and all external secretions contain antibodies to human immunodeficiency virus (HIV), their levels, specificity, isotypes, and relevant effector functions display a great degree of variability. Antibodies that bind HIV antigens and neutralize the virus are predominantly associated with the IgG isotype in sera and in all external secretions, even where total levels of IgG are much lower than those of IgA. Rectal fluid that contains high IgA, but low IgG levels, displayed low neutralizing activity independent of antibodies. Therefore, external secretions should be evaluated before and after selective depletion of Ig. At the systemic level, HIV-specific IgA may interfere with the effector functions of IgG, as suggested by recent studies of individuals systemically immunized with an experimental HIV vaccine. Although HIV-specific IgG and IgA antibodies may exhibit their protective activities at mucosal surfaces through interference with viral entry and local neutralization at the systemic level, such antibodies may display discordant effector functions.

Department of Microbiology University of Alabama at Birmingham Birmingham AL USA; Institute of Immunology and Microbiology Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Mestecky J. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract as compared to other mucosal sites. J Reprod Immunol. 2007;73:86–97. PubMed

Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol. 2009;83:196–200. PubMed PMC

Mestecky J, Raska M, Novak J, Alexander RC, Moldoveanu Z. Antibody–mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J Reprod Immunol. 2010;85:81–85. PubMed PMC

Wira C, Fahley J. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008;22:1909–1917. PubMed PMC

Jackson S, Mestecky J, Moldoveanu Z, Spearman P. Appendix I: collection and processing of human mucosal secretions. In: Mestecky J, Lamm ME, Mayer L, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal Immunology. 3rd edn. Amsterdam, The Netherlands: Elsevier Academic Press; 2005. pp. 1647–1659.

Kutteh WH, Mestecky J, Wira CR. In: Mucosal immunity in the human female reproductive tract. Mestecky J, Lamm ME, Mayer L, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Amsterdam, The Netherlands: Elsevier Academic Press; 2005. pp. 1631–1646.

Kutteh WH, Prince SJ, Hammonds KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol. 1996;104:538–542. PubMed PMC

Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, VanCott TC, Trabottoni D, Sannella E, Mestecky J. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 2002;18:1291–1300. PubMed

Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, Moldoveanu Z, Alexander RC, Kulhavy R, Pastori C, Maboko L, Riedner G, Zhu Y, Wrinn T, Hoelscher M. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Human Retroviruses. 2011;27:469–486. PubMed PMC

Jackson S, Prince S, Kulhavy R, Mestecky J. False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV-1 antigens. AIDS Res Hum Retroviruses. 2000;16:595–602. PubMed

Moldoveanu Z, Mestecky J. Mucosal antibody responses to HIV. In: Prasad VR, Kalpana GV, editors. HIV Protocols. 2nd edn. Vol. 48. New York: Humana Press / Springer Science; 2009. pp. 333–345. Methods Mol Biol.

Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince S, Sabbaj S, Mulligan MJ, Goepfert PA. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-1-infected individuals. AIDS Res Hum Retroviruses. 2004;20:972–988. PubMed

Mohamed OA, Ashley R, Goldstein A, McElrath J, Dalessio J, Corey L. Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent western blot immunodetection method. J Acquir Immune Defic Syndr. 1994;7:375–380. PubMed

Wei Q, Moldoveanu Z, Huang WQ, Alexander RC, Goepfert PA, Mestecky J. Comparative evaluation of HIV-1 neutralization in external secretions and sera of HIV-1-infected women. Open AIDS J. 2012;6:293–302. PubMed PMC

Mestecky J, Alexander RC, Wei Q, Moldoveanu Z. Methods of evaluation of humoral immune responses in human genital tract secretions. Am J Reprod Immunol. 2011;65:361–367. PubMed PMC

Tamaras GD, Haynes BF. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS. 2009;4:373–379. PubMed PMC

Overbaugh J, Morris L. The antibody response against HIV-1. In: Bushman FD, Nabel GJ, Swanstrom R, editors. Cold Spring Harbor Perspectives In Medicine. Cold Spring Harbor Laboratory Press; 2012. pp. 1–19. PubMed PMC

Alexander R, Mestecky J. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr HIV Res. 2007;5:588–593. PubMed

Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. In: Bushman FD, Nabel GJ, Swanstrom R, editors. Cold Spring Harbor Perspectives in Medicine. Cold Spring Harbor Laboratory Press; 2011. pp. 1–17. PubMed PMC

Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011;85:4927–4936. PubMed PMC

Brombin C, Diomede L, Tudor D, Drillet AS, Pastori C, Poli E, Riva A, Uberti-Foppa C, Galli M, Di Serio C, Bomsel M, Lopalco L. A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients. PLosOne. 2013;8:1–13. PubMed PMC

Mcneely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor:a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456–464. PubMed PMC

Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis. 1997;3:64–69. PubMed

Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol. 2006;13:1111–1118. PubMed PMC

Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Bio Metals. 2004;17:189–196. PubMed

Raska M, Novak J. Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp. 2010;58:191–208. PubMed

Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648–659. PubMed PMC

Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, Shaw GM. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 1988;334:440–444. PubMed

Keele BF, Giorgi EE, Salazar-Gonzalez F, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, We X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552–7557. PubMed PMC

Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Oshenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:1273–1289. PubMed PMC

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. PubMed

Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem. 2010;285:20860–20869. PubMed PMC

Amin MN, McLellan JS, Huang W, Orwenyo J, Burton DR, Koff WC, Kwong PD, Wang LX. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol. 2013;9:521–526. PubMed PMC

Berneman A, Belec L, Fischetti VA, Bouvet JP. The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun. 1998;66:4163–4168. PubMed PMC

Mestecky J, Moldovenu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005;53:208–214. PubMed

Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 2002;4:667–677. PubMed

Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol. 1987;7:265–276. PubMed

Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PNP, Sung An D, Yang L, Baltimore D. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood. 2012;120:4571–4582. PubMed PMC

Kozlowski PA, Jackson S. Serum IgA subclasses and molecular forms in HIV infection: selective increase in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retroviruses. 1992;8:1773–1780. PubMed

Murphy BR. Mucosal immunity to viruses. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal Immunology. 3rd edn. Amsterdam, The Netherlands: Elsevier Academic Press; 2005. pp. 799–813.

Holmgren J, Svennerholm A-M. Mucosal immunity to bacteria. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal Immunology. 3rd edn. Amsterdam, The Netherlands: Elsevier Academic Press; 2005. pp. 783–798.

Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Blondeau C. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. J Immunol Methods. 1999;222:111–124. PubMed

Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Bloudeau C. Comparison of antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses. 1999;15:1365–1376. PubMed

Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Gouin E, Sicard D, Blondeau C. IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses. 2000;6:583–594. PubMed

Chaoul N, Burelout C, Peruchon S, van Buu BN, Laurent P, Proust A, Raphael M, Garraud O, Le Grand R, Prevot S, Richard Y. Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus. Retrovirology. 2012;9:43. PubMed PMC

Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. AIDS. 1995;9:695–700. PubMed

Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Induction and expression of intestinal humoral immunity in HIV-infected individuals: prospects for vaccination against secondary enteric infections. Pathobiology. 1998;66:176–182. PubMed

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA. 2011;108:11181–11186. PubMed PMC

Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine. 2002;20:1922–1925. PubMed

Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003;9:343–346. PubMed

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75:8340–8347. PubMed PMC

Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol. 2010;22:1–9. PubMed PMC

Mascola JR. Define the protective antibody response for HIV-1. Curr Mol Med. 2003;3:209–216. PubMed

Lamm ME. Protection of mucosal epithelia by IgA: intracellular neutralization and excretion of antigens. In: Kaetzel CS, editor. Mucosal Immune Defense: Immunoglobuin A. New York: Springer Science+Business Media, LLC; 2007. pp. 173–182.

Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corthesy B, Neutra MR, Burton DR, Janoff EN. Inhibitionof HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol. 2007;179:3144–3152. PubMed PMC

Wright A, Lamm ME, Huang YT. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol. 2008;82:11526–11535. PubMed PMC

Huang YT, Wright A, Gao X, Kulick L, Yan H, Lamm M. Intraepithelial cell neutralization of HIV-1 replication. J Immunol. 2005;174:4828–4835. PubMed

Dembert T, Robert-Guroff M. Mucosal immunity and protection against HIV / SIV infection: strategies and challenges for vaccine design. Int Rev Immunol. 2009;28:20–48. PubMed PMC

Woof JM, Mestecky J. Mucosal Immunoglobulins. Immunol Rev. 2005;206:64–82. PubMed

Mestecky J, Russell MW. Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces. Immunol Lett. 2009;124:57–62. PubMed PMC

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao H-X, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, deSouza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. Immune-correlates analysis of an HIV-1 vaccine efficacy trail. N Eng J Med. 2012;366:1275–1286. PubMed PMC

Russell MW, Kilian M. Biological activities of IgA. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal Immunology. 3rd edn. Amsterdam, The Netherlands: Elsevier Academic Press; 2005. pp. 267–289.

Xu W, Santini PA, Sullivan JS, He B, Shan M, Ball SC, Dyer WB, Ketas TJ, Chadburn A, Cohen-Gould L, Knowles DM, Chiu A, Sanders RW, Chen K, Cerutti A.

Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006;7:302–310. PubMed

Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA. 2011;108:4388–4393. PubMed PMC

Crowley-Nowick PA, Bell M, Edwards RP, McCallister D, Gore H, Kanbour-Shakir A, Mestecky J, Partridge EE. Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion. Am J Reprod Immunol. 1995;34:214–247. PubMed

Gupta S, Becerra JC, Gach JS, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping L-H, Corti D, Moldt B, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN. The neonatal Fc receptor (FcRn) enhances transcytosis of IgG-bound HIV-1 across intact epithelial monolayers. PLos Pathogens. 2013;9:e1003776. PubMed PMC

Kibe T. Glycosylation and placental transport of immunologlobulin G. J Clin Biochem Nutr. 1996;21:57–63.

Forthal DN, Gash JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. Fc-glycosylation influences receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010;185:6876–6882. PubMed

Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection